Halozyme Therapeutics's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 109.31.
Halozyme Therapeutics's Days Inventory for the
three
months ended in Mar. 2026 was 191.13.
Halozyme Therapeutics's Days Payable for the
three
months ended in Mar. 2026 was 20.15.
Therefore, Halozyme Therapeutics's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 280.29.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Halozyme Therapeutics Cash Conversion Cycle Related Terms
Halozyme Therapeutics Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HALO vs KYMR, IBRX, PRAX: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Halozyme Therapeutics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics (HALO) has a Cash Conversion Cycle of 280.29 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Cash Conversion Cycle too high?
Halozyme Therapeutics' current Cash Conversion Cycle is 280.29. The Biotechnology industry median Cash Conversion Cycle is 103.08. Halozyme Therapeutics' value of 280.29 is 171.9% above this industry median. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Cash Conversion Cycle compare to KYMR and IBRX?
Halozyme Therapeutics' Cash Conversion Cycle of 280.29 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.08. Halozyme Therapeutics' value of 280.29 is 171.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.08, based on 871 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current Cash Conversion Cycle of 280.29 is 171.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current Cash Conversion Cycle is 280.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.60, compared to a current price of $76.77 — trading 15.3% below its estimated fair value. The current Cash Conversion Cycle is 280.29 and 171.9% above the Biotechnology industry median of 103.08. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Cash Conversion Cycle is 280.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $76.77 is trading 15.3% below its estimated GF Value™ of $90.60.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
Cash Conversion Cycle: 280.29
GF Value™: $90.60 vs. price of $76.77 (15.3% below fair value)
Industry Position: 171.9% above the Biotechnology median
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score
Get the complete analysis for HALO
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
